Biocon — a top-5 biosimilars franchise still digging out of its own acquisition debt

The Pulse

Biocon is one of the five largest biosimilars makers in the world and one of three big insulin players — a genuinely hard-to-build global franchise sitting inside an Indian listed company. The catch is that it paid for that scale with debt: the $2 billion acquisition of Viatris’s biosimilars business in 2022, funded by borrowing that roughly tripled the company’s debt (from ₹5,147 crore to ₹18,019 crore in one year), vaulted revenue past ₹16,900 crore but left interest (₹990 crore a year) and amortisation (~₹1,957 crore a year) swallowing almost all the operating profit. The result is a company doing ₹3,455 crore of operating profit but only ₹369 crore of net profit, a return on equity of 1.4%, and a P/E of 174 that means nothing. The entire story across the last year is the dig-out: two equity raises that diluted the promoter family from 60.6% to 44.9%, structured debt retired, net debt cut from over $1.5 billion to ~$1.1 billion, two rating upgrades, and a steady drumbeat of “FY27 is the inflection year.” The franchise is real and the cleanup is real. Whether the returns ever justify the price paid is the open question.

The Business

Biocon has three engines. The big one is Biocon Biologics — biosimilars, 58% of revenue. A biosimilar is a near-copy of an expensive biologic drug once its patent expires; think of it as the generic version of a medicine that’s grown in living cells rather than mixed in a vat, which is why it’s so much harder to make. You can’t just reverse-engineer it — you need FDA- and EMA-approved facilities, years of trials, and deep manufacturing know-how. That difficulty is the moat: only a handful of companies on earth do this at scale (Sandoz, Amgen, Celltrion, Samsung Bioepis, Biocon), and Biocon is vertically integrated, making its own drug substance. It has 10 approved biosimilars across diabetes, cancer, immunology and eye disease, sells in 120+ countries, and is one of only three global insulin players — notably the only approved US biosimilar-insulin maker just as Novo Nordisk retreats from some insulin lines. The recent launch wave is its best argument: ustekinumab (Yesintek) already at ~20% US share and 70%+ formulary coverage, denosumab and bevacizumab launched, aflibercept (Yesafili, an eye drug) cleared for US launch in H2 FY27 via a confidential settlement with the originator, and four molecules now above $200 million each.

The second engine is Generics — APIs and formulations, lower-margin (8–12%), currently squeezed by the cost of newly commissioned facilities, but carrying the company’s interesting GLP-1 bet: liraglutide (a weight-loss/diabetes peptide) already approved and selling in the EU, with semaglutide filings behind it, all vertically integrated. The third is Syngene, a separately listed contract research-and-manufacturing arm (a “CRDMO” — labs-for-hire to global pharma) that earns ~25–30% margins and just extended a partnership with Bristol Myers Squibb to 2035, though it’s in a soft patch on a single large client.

The thread management keeps pulling is vertical integration and its mantra of “value-maximise, not share-maximise” — pricing for profit rather than chasing volume in a business where biosimilar prices erode relentlessly the moment competitors arrive. The founder, Kiran Mazumdar-Shaw, still chairs and remains the public face and emotional centre of the story.

How Management Thinks

Two things stand out, one reassuring and one not. The reassuring one: on capital allocation now, management is disciplined and specific. They did Biocon’s first equity raise since its 2004 IPO — two QIPs totalling ~₹4,500 crore-plus — and used the cash with precision, retiring three expensive structured-debt lenders (Goldman, Kotak, Edelweiss) on a named, quarter-by-quarter cadence, then bought out the Biocon Biologics minorities and folded it fully into the listed parent (“Biocon One”). Capex is winding down to maintenance, all free cash is earmarked for debt, both rating agencies upgraded, and they were candid enough to drop an oral-insulin programme explicitly “on ROCE grounds.” That’s a management cleaning up a mess competently.

The unreassuring one is what created the mess. The Viatris deal was a debt-funded mega-acquisition whose returns have so far been dismal — ROCE fell from 12–13% to under 4% — and the cleanup itself, a dilutive equity raise at a depressed price, is the bill for that leverage. On the Q1 call a long-term investor put it bluntly: the market cap had fallen below the debt despite roughly $2 billion spent on Viatris. Mazumdar-Shaw conceded the debt “drags perception” but insisted the acquisition is “game-changing” and that Biocon will be a top-5 biosimilars leader in five years. The other tell is a reflexive refusal to be pinned down: across all four calls, management narrates momentum warmly but “takes offline” almost every hard quantitative question — the granular parent-versus-subsidiary debt split, market-share numbers, a ₹760 crore accounting reclassification — and declines to guide on sustainable margins. They are promotional about the destination and slippery about the arithmetic. To their credit, the operational promises they do make — a five-launch commitment, the debt-retirement schedule, biosimilars turning EBITDA-positive — have largely been kept.

Where It’s Going

The whole investment case is compressed into one word management repeats: inflection, and they keep pointing at FY27. The logic is mechanical and not unreasonable. Operating profit is steady (~20–23% margins, biosimilars in the mid-20s). As the retired debt rolls off, roughly ₹300 crore a year of interest savings drop to the bottom line from FY27. The launch wave — aflibercept and an insulin-aspart ramp off a doubled Malaysian line, both weighted to H2 FY27 — adds revenue without much new capital. Put those together and the depressed ₹369 crore net profit should expand sharply even if the top line only grows mid-teens. That’s the bull case the ₹68,000 crore market cap is paying for.

The tensions are equally clear. Biosimilars are structurally price-eroding — management flagged that a strong Q3 biosimilar margin came from a deliberate, non-repeatable US mix-shift and told analysts flatly not to extrapolate it. Syngene is soft and concentrated on a couple of large clients. The GLP-1 generics bet is promising but margin-dilutive while facilities ramp. Net debt is still ~$1.1 billion, the bulk maturing as 2029 bonds, so the deleveraging is real but not finished. And there is no firm Biocon Biologics IPO — the Viatris-era commitment is “best-effort,” so the often-cited “unlock” is not a scheduled event. The direction of travel is genuinely better than two years ago; the question is whether a top-5 global biosimilars franchise can ever earn a return on the ~$2 billion it cost to assemble.

The Four Checks

Quality & moat (gate) — 6/10. Real, but eroding. The barriers to biosimilars are among the highest in generic-style pharma — approved biologics facilities, trial data, manufacturing mastery, a global club of maybe five players — and Biocon’s insulin position is a near-oligopoly. That’s a genuine edge. But the end market is built on undercutting originator prices, so the surplus erodes with every new competitor, and biosimilar revenue actually plateaued around ₹90 billion in FY24–FY25. A strong, hard-to-replicate franchise selling into a structurally price-competitive market. Good business, contestable economics.
Returns on incremental capital & runway — 4/10. The runway is large — a deep launch pipeline, four $200m molecules, GLP-1 optionality — but the demonstrated return on reinvested capital has been poor. ROCE sits at ~3.75% and ROE at 1.4%; the ~$2 billion poured into Viatris has so far earned well below the cost of that capital. There’s a credible path up (operating leverage on a built-out base, interest rolling off), but it’s a forecast, not a record. You’re underwriting a recovery in returns that hasn’t yet shown in the numbers.
Capital allocation for the stage — 5/10. Mixed, and the mix is the whole story. The original sin — a debt-funded acquisition at a price that crushed returns and forced a dilutive rescue equity raise at a depressed stock — is a serious demerit. Against that, the recent execution is rational and disciplined: precise debt retirement, minority buyout, capex restraint, killing a low-ROCE programme, low dividends while deleveraging. A competent cleanup of a self-inflicted wound nets out to middling.
Price — 3/10. Demanding. The P/E of 174 is noise (temporarily crushed earnings), so judge it on enterprise value: ~₹68,000 crore of equity plus ~₹10,000 crore of net debt against ~₹4,700 crore of core EBITDA is roughly 16–17x — full for a business earning sub-4% ROCE today, and the entire premium rests on the FY27 inflection arriving on schedule. Little margin of safety if biosimilar margins erode faster or the launches disappoint.

Engine score: 15/30 (moat 6 + reinvestment 4 + allocation 5), price-blind. Price 3/10 separately. A high-quality, hard-to-build global franchise whose compounding engine has been jammed for three years by the debt and amortisation of the acquisition that built it — now being unjammed, but priced as though the unjamming is already done.

Sources

Concall transcripts read: Q1 FY26 (call 8 Aug 2025), Q2 FY26 (12 Nov 2025), Q3 FY26 (13 Feb 2026), Q4 FY26 + full-year (8 May 2026) — four transcripts obtained and digested.
Concall gaps: the manifest also listed quarters with no transcript link (a Nov-2025 and a May-2026 filing) and duplicate entries — these were screener listing artefacts; the four substantive quarterly calls covering all of FY26 were captured.
Annual reports: FY23, FY24, FY25 (sections extracts). The trimmed AR section files came back thin — the chairman’s letters and full MD&A (Viatris integration, debt roadmap, pipeline) did not survive the cleaning pass — so the multi-year qualitative arc rests primarily on the four concalls and the screener snapshot, with the ARs contributing segment revenue/margin figures only.
Snapshot: screener.in consolidated, fetched 2026-06-16 (logged-out session).
Research subfolder: vault/Sources/Earnings/Biocon Ltd/ (digests + transcripts + snapshot; not published).
Quirks to note: reported net profit is heavily distorted by lumpy “Other Income” one-offs (₹1,166 cr gain in Jun-2024; −₹176 cr in Dec-2025, which produced a −₹52 cr loss quarter) and by acquisition amortisation — operating profit (₹3,455 cr FY26) and core EBITDA are the truer read of the underlying business than headline PAT.